Spherix Global Insights Expands Therapeutic Area Coverage into Hematology
June 10, 2024 04:00 ET
|
Spherix Global Insights
EXTON, PA, June 10, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry,...
Global Hemoglobinopathies Market is Expected to Reach $7.0 Billion by 2031: Says AMR
August 25, 2022 08:33 ET
|
Allied Market Research
Portland, OR, Aug. 25, 2022 (GLOBE NEWSWIRE) -- The Global Hemoglobinopathies Market size was estimated at $4.2 billion in 2021 and is expected to hit $7.0 billion by 2031, registering a CAGR of...
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 04, 2021 07:00 ET
|
Imara, Inc.
Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at...
Imara Reports First Quarter 2021 Financial Results and Business Highlights
May 11, 2021 07:00 ET
|
Imara, Inc.
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the...
Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights
May 04, 2021 07:00 ET
|
Imara, Inc.
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Announces Appointment of Stephen M. Migausky as General Counsel
May 04, 2020 07:00 ET
|
Imara, Inc.
BOSTON, May 04, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
IMARA Announces Pricing of Initial Public Offering
March 11, 2020 21:57 ET
|
Imara, Inc.
BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to...